Pelthos Therapeutics Inc.
PTHS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | -0.00 | -0.01 | 0.88 |
| FCF Yield | -83.54% | -14.41% | -23.03% | 0.00% |
| EV / EBITDA | -1.20 | -1.16 | -3.15 | 0.00 |
| Quality | ||||
| ROIC | 1,434.03% | 132.58% | 73.22% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.13 | 0.64 | – |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -490.45% | 37.40% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.23 | -0.17 | -0.21 | 0.00 |
| Interest Coverage | -9.63 | -13.23 | -16.51 | -3,316.19 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |